Intellia Therapeutics

Youtube Subscribe

Open: 44.97 Close: 43.64 Change: -1.33

The top 10 things about Intellia Therapeutics Company Inc Stock found by an AI.

How much time have you spent trying to decide whether investing in Intellia Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Intellia Therapeutics are: …

Concept Map

Semantic Network

Stock Summary

Intellia Therapeutics Inc. (NTLA) Director Muna Bhanji sold 1,867 shares of the company in a transaction on Thursday, July 6th. Director Munani Bhanj now holds 12.

Today's Summary

Director Muna Bhanji sold 1,867 shares of the company in a transaction on Thursday, July 6th. NTLA does not generate passive income.

Today's News

Intellia Therapeutics Inc. (NTLA) Director Muna Bhanji sold 1,867 shares of the company in a transaction on Thursday, July 6th. Cyndeo Wealth Partners LLC acquired a new position in Intellya Therapeutic, Inc. in Stock. Intellia Therapeutics is anticipated to post earnings of ($4.05) per share for the year. This forecast comes amidst a consensus estimate of $5.33 per share. Director Muna Bhanji now holds 12,526 shares in the company valued at $492,271. Wall Street analysts think its a good time to buy Intellia Therapeutics stock. Out of 16 sell side analysts who give forecasts on NTLA, the consensus analyst rating is a Strong Buy. NTLA does not generate passive income. Cambridge, MA, is hiring associate director, clinical data management in cambridge, massachusetts, united states. Sandia Investment Management LP acquired a new position in shares of Intellia Therapeutics in the fourth quarter valued at approximately $35,000. CWM LLC boosted its holdings in shares by 2,072.7% in the first quarter. Raymond James & Associates owns 0.06% of Intellia Therapeutics worth $1,972,000 at the end of the most recent quarter. Director Muna Bhanji sold 1,867 shares of the businesss stock in a transaction on Thursday, July 6th.

Stock Profile

" Intellia Therapeutics Inc. (NTLA) Director Muna Bhanji sold 1,867 shares of the company in a transaction on Thursday, July 6th. Cyndeo Wealth Partners LLC acquired a new position in Intellya Therapeutic, Inc. in Stock. Intellia Therapeutics is anticipated to post earnings of ($4.05) per share for the year. This forecast comes amidst a consensus estimate of $5.33 per share. Director Muna Bhanji now holds 12,526 shares in the company valued at $492,271. Wall Street analysts think its a good time to buy Intellia Therapeutics stock. Out of 16 sell side analysts who give forecasts on NTLA, the consensus analyst rating is a Strong Buy. NTLA does not generate passive income. Cambridge, MA, is hiring associate director, clinical data management in cambridge, massachusetts, united states. Sandia Investment Management LP acquired a new position in shares of Intellia Therapeutics in the fourth quarter valued at approximately $35,000. CWM LLC boosted its holdings in shares by 2,072.7% in the first quarter. Raymond James & Associates owns 0.06% of Intellia Therapeutics worth $1,972,000 at the end of the most recent quarter. Director Muna Bhanji sold 1,867 shares of the businesss stock in a transaction on Thursday, July 6th."

Keywords

This document will help you to evaluate Intellia Therapeutics without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Intellia Therapeutics are: share, Intellia, Therapeutics, NTLA, Director, Muna, Bhanji, and the most common words in the summary are: therapeutic, intellia, stock, market, inc, price, share, . One of the sentences in the summary was: NTLA does not generate passive income.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #intellia #stock #market #inc #price #share.

Read more →

Youtube Subscribe

---